Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Therapy for relapsed or refractory acute myeloid leukemia (AML) remains challenging.
• Timed sequential salvage combination cytotoxic chemotherapy is a potential strategy for AML.
• The EMA regimen (etoposide, mitoxantrone, cytarabine) is being investigated for AML treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of the EMA regimen in adult patients with relapsed or refractory AML.
• To determine the complete remission rate and identify adverse events associated with EMA chemotherapy.

Main Methods:

• A single-center, sequential treatment of ten adult patients with relapsed or refractory AML.
• Administration of EMA regimen: cytarabine (days 1-3, 8-10), mitoxantrone (days 1-3), and etoposide (days 8-10).
• Monitoring for complete remission and adverse events, including cytopenia and infections.

Main Results:

• An overall complete remission rate of 40% was observed.
• Three out of four patients with relapsed disease achieved complete remission.
• The regimen was associated with prolonged cytopenia and a high incidence of infectious adverse events.

Conclusions:

• The EMA regimen demonstrated a 40% complete remission rate in relapsed/refractory AML, particularly in relapsed cases.
• Prolonged cytopenia and infectious complications are significant concerns with EMA therapy.
• EMA is best reserved for relapsed AML patients with curative intent before allogeneic hematopoietic cell transplant.